Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Fudan University

Status: Enrolling

Conditions: Refractory Colorectal Carcinoma; Metastatic Colorectal Cancer; Colorectal Cancer

Treatments: Drug: Fruquintinib Combined With TAS-102

Study type: Observational

Funder types: Other

Identifiers

NCT06221423

Fru plus TAS-102 in mCRC

Details and patient eligibility

About

Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histology-confirmed metastatic CRC (mCRC)
• Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
• Fruquintinib administered as salvage treatment
• Age: 18-75 years old
• Informed consent

Exclusion criteria

• Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy
• Fruquintinib and/or TAS-102 administration as second-line treatment
• Drug administration stopped after less than two cycles

Trial design

20 participants in 1 patient group

Fru plus TAS-102

Description:

mCRC patients receiveing Fruquintinib combined with TAS-102 in third- or late- line

Treatment:

Drug: Fruquintinib Combined With TAS-102